---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-004527"
form_type: "8-K"
ticker: "PMN"
cik: "0001374339"
company_name: "ProMIS Neurosciences Inc."
filed_at: "2024-04-01T23:59:59+00:00"
generated_at: "2026-06-04T04:24:15.700206+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ProMIS Neurosciences reports FY2023 net loss $13.2M, cash $12.6M; PMN310 Phase 1a data on track for mid-2024

## Summary
- Cash and cash equivalents $12.6M at Dec 31, 2023, up from $5.9M; Q3 2023 PIPE raised $20.4M gross.
- Net loss $13.2M for FY2023 vs $18.1M in FY2022; R&D expenses $7.9M vs $16.1M.
- Phase 1a trial of PMN310 for Alzheimer's dosed Nov 2023; top-line safety/PK data expected mid-2024.
- Lead vaccine candidate PMN400 selected for synucleinopathies (MSA, Parkinson's) in Jan 2024.
- Neil Warma appointed interim CEO in Jan 2024; US/international patent allowances for AD antibody in Mar 2024.

## SEC filing metadata
- accession: 0001558370-24-004527
- form_type: 8-K
- ticker: PMN
- cik: 0001374339
- company_name: ProMIS Neurosciences Inc.
- filed_at: 2024-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374339/000155837024004527/0001558370-24-004527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374339/000155837024004527/pmn-20240401x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-004527
- JSON: https://secwatch.observer/filing/0001558370-24-004527.json
- Plain text: https://secwatch.observer/filing/0001558370-24-004527.txt

## Key facts
- Earnings Releases
  ProMIS Neurosciences Inc. reported the fiscal year ended December 31, 2023 results: net income $13.2 million.
  - Period: the fiscal year ended December 31, 2023
  - Net income: $13.2 million
  - Result: reported results
  source text: Net loss was $13.2 million for the full year ended December 31, 2023, compared to a net loss of $18.1 million for full year in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1374339/000155837024004527/0001558370-24-004527-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.